Unknown

Dataset Information

0

CXC-chemokine receptor 4 antagonist AMD3100 promotes cardiac functional recovery after ischemia/reperfusion injury via endothelial nitric oxide synthase-dependent mechanism.


ABSTRACT: CXC-chemokine receptor 4 (CXCR4) regulates the retention of stem/progenitor cells in the bone marrow (BM), and the CXCR4 antagonist AMD3100 improves recovery from coronary ligation injury by mobilizing stem/progenitor cells from the BM to the peripheral blood. Thus, we investigated whether AMD3100 also improves recovery from ischemia/reperfusion injury, which more closely mimics myocardial infarction in patients, because blood flow is only temporarily obstructed.Mice were treated with single subcutaneous injections of AMD3100 (5 mg/kg) or saline after ischemia/reperfusion injury. Three days later, histological measurements of the ratio of infarct area to area at risk were smaller in AMD3100-treated mice than in mice administered saline, and echocardiographic measurements of left ventricular function were greater in the AMD3100-treated mice at week 4. CXCR4(+) cells were mobilized for just 1 day in both groups, but the mobilization of sca1(+)/flk1(+) cells endured for 7 days in AMD3100-treated mice compared with just 1 day in the saline-treated mice. AMD3100 upregulated BM levels of endothelial nitric oxide synthase (eNOS) and 2 targets of eNOS signaling, matrix metalloproteinase-9 and soluble Kit ligand. Furthermore, the loss of BM eNOS expression abolished the benefit of AMD3100 on sca1(+)/flk1(+) cell mobilization without altering the mobilization of CXCR4(+) cells, and the cardioprotective effects of AMD3100 were retained in eNOS-knockout mice that had been transplanted with BM from wild-type mice but not in wild-type mice with eNOS-knockout BM.AMD3100 prolongs BM progenitor mobilization and improves recovery from ischemia/reperfusion injury, and these benefits appear to occur through a previously unidentified link between AMD3100 and BM eNOS expression.

SUBMITTER: Jujo K 

PROVIDER: S-EPMC3560409 | biostudies-literature | 2013 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

CXC-chemokine receptor 4 antagonist AMD3100 promotes cardiac functional recovery after ischemia/reperfusion injury via endothelial nitric oxide synthase-dependent mechanism.

Jujo Kentaro K   Ii Masaaki M   Sekiguchi Haruki H   Klyachko Ekaterina E   Misener Sol S   Tanaka Toshikazu T   Tongers Jörn J   Roncalli Jérôme J   Renault Marie-Ange MA   Thorne Tina T   Ito Aiko A   Clarke Trevor T   Kamide Christine C   Tsurumi Yukio Y   Hagiwara Nobuhisa N   Qin Gangjian G   Asahi Michio M   Losordo Douglas W DW  

Circulation 20121130 1


<h4>Background</h4>CXC-chemokine receptor 4 (CXCR4) regulates the retention of stem/progenitor cells in the bone marrow (BM), and the CXCR4 antagonist AMD3100 improves recovery from coronary ligation injury by mobilizing stem/progenitor cells from the BM to the peripheral blood. Thus, we investigated whether AMD3100 also improves recovery from ischemia/reperfusion injury, which more closely mimics myocardial infarction in patients, because blood flow is only temporarily obstructed.<h4>Methods an  ...[more]

Similar Datasets

| S-EPMC3586978 | biostudies-literature
| S-EPMC2892600 | biostudies-literature
| S-EPMC3540195 | biostudies-literature
| S-EPMC2763350 | biostudies-literature
| S-EPMC141066 | biostudies-literature
2021-01-18 | GSE164521 | GEO
| S-EPMC4917647 | biostudies-literature
2023-06-01 | PXD040726 | Pride
| S-EPMC4925993 | biostudies-literature
| S-EPMC9076604 | biostudies-literature